Document Detail


Biomarkers, subgroup evaluation, and clinical trial design.
MedLine Citation:
PMID:  22463794     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Advances in clinical and basic sciences are raising the potential to use genetic and clinical biomarkers to identify a subgroup of patients who would most likely benefit from treatment, and to evaluate the benefit of treatment in that subgroup. To make full use of this potential, special clinical trial designs and analyses are needed. For identifying and evaluating a subgroup based on a single continuous biomarker, the most informative approach is the biomarker-analysis design, which is a randomized trial whose analysis involves estimation of the treatment benefit within patient groups defined with respect to various cutpoints or intervals of the biomarker. For identifying and evaluating a subgroup considering a range of possible markers, the adaptive signature design is recommended. In the adaptive signature design, participants are randomly split into training and test samples, a rule for creating the subgroup is formulated in the training sample, and treatment benefit is estimated in the test sample. The adaptive signature design can be usefully extended via the sliding-window subgroup plot that was originally developed for the biomarker-analysis design.
Authors:
Stuart G Baker; Barnett S Kramer; Daniel J Sargent; Marco Bonetti
Related Documents :
22429434 - Therapeutic identification of depression in young people: lessons from the introduction...
22296314 - Studies of long-term use of antidepressants: how should the data from them be interpreted?
22564354 - Non-inferiority study design: lessons to be learned from cardiovascular trials.
7278884 - Quality of institutional participation in multicenter clinical trials.
20054744 - Does amantadine have favourable effects on fatigue in persian patients suffering from m...
10588144 - Clinical follow-up after cessation of chronic electrical neuromodulation in patients wi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Discovery medicine     Volume:  13     ISSN:  1944-7930     ISO Abbreviation:  Discov Med     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-04-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101250006     Medline TA:  Discov Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  187-92     Citation Subset:  IM    
Affiliation:
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Manganese is required for oxidative metabolism in unstressed Bradyrhizobium japonicum cells.
Next Document:  The impact of antibiotics on the gut microbiota as revealed by high throughput DNA sequencing.